Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Newborn Screening topic
No spam. Unsubscribe anytime.
Committee sends bill for newborn Duchenne screening to the floor after debate on costs and benefits
Summary
On April 1, 2025 the Insurance and Real Estate Committee voted to send HB 6919, which would require newborn screening for Duchenne muscular dystrophy, to the floor. Members discussed estimated Department of Public Health costs, potential benefits of early diagnosis and the need for mandate review.
The Insurance and Real Estate Committee voted April 1, 2025, to send HB 6919 — an act requiring newborn screening for Duchenne muscular dystrophy — to the House floor after members discussed program costs, clinical benefit and implementation.
Committee staff described the estimated fiscal impact to the Department of Public Health as $337,000 in fiscal 2027 and $319,000 in fiscal 2028, and noted the comptroller’s office estimated $56,000 in both fiscal 2027 and fiscal 2028; staff said the DPH estimate includes added staff to administer the screening. Committee members also referenced that the state records about 35,000 births per year.
Representative Pavlok Damato asked whether the screening would be statewide and whether it would change clinical outcomes. Janet from the Office of Legislative Research summarized the bill analysis, saying Duchenne is “a severe form of muscular dystrophy characterized by progressive muscle degeneration and weakness” that presents between ages 2 and 3 and primarily affects males. Senator Wong and other members described the screening as an early diagnostic tool that could allow families and clinicians to begin targeted therapies sooner; Senator Wong said early diagnosis can improve planning and potentially extend life expectancy.
Representative Meskers, who said he had personal experience caring for a family member with muscular dystrophy, urged support and described the disease as having no current cure but treatments that can improve quality of life. Representative Pavlok Damato said he would vote no to obtain more information about treatment options and long‑term outcomes before approving a mandate.
The motion to send HB 6919 to the floor was moved by Senator Hoenig and seconded by Senator Cabrera. The committee recorded affirmative votes and referred the bill to the floor. Members left the roll open until early afternoon for any additional votes.
Notes: Committee discussion emphasized the trade‑off between early detection and state fiscal impacts; staff provided specific fiscal estimates and OLR provided the clinical summary in response to members’ questions.
